the Relationship of the Use of Eye Masks and Outcomes of Patients With Sepsis in Intensive Care Unit
NCT ID: NCT02304224
Last Updated: 2014-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2014-12-31
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Clinical data collection Data such as patient's age, gender, contact information, time from onset to admission, existence of septic shock, pathogen species, the site of infection, the existence of organ dysfunction, APACHE II score (Acute Physiology And Chronic Health Evaluation Scoring System) , SOFA (Sequential Organ Failure Assessment)score, the use of mechanical ventilation, vasoactive drugs, corticosteroids, sedative and analgesic medication, history of eye diseases and neurological diseases is collected from each patient who is included in the study. Follow-up data for daily daytime sleep time, existence of delirium, CPC score and GCS score on Day 7 and Day 28, length of stay and survival of 28 days after admission is also collected.
3. Sample collection and processing The blood samples collected in citrate anticoagulation tubes and the urine samples collected in specialized graduated cylinders are stored at room temperature. Staining and fixation were performed within 24 h after blood collection. The expression of Monocyte Human Leukocyte Antigen-DR is detected using flow cytometer. The concentration of 6-sulfatoxymelatonin in urine is detected by ELISA kit.
4. Cerebral Performance Category (CPC) CPC is a 5-category scale for measuring neurological status 2 weeks after cardiac arrest and CPC score 6 months after cardiac arrest. The 5 categories are: CPC 1, conscious and alert with good cerebral performance; CPC 2, conscious and alert with moderate cerebral performance; CPC 3, conscious with severe cerebral disability; CPC 4, comatose or in persistent vegetative state; and CPC 5, brain dead, circulation preserved.
5. Glasgow Coma Scale (GCS) The GCS was developed as a standardized method for healthcare practitioners to evaluate degree of altered consciousness in patients who had sustained head injuries. The GCS is comprised of three categories: eye opening, verbal response, and motor response. The score from each category is summed, to provide a total GCS score (range 3-15).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
the patients with sepsis admitted in the intensive care unit aren't applied with eye masks at night
No interventions assigned to this group
Eye masks
the patients with sepsis in the intensive care unit are applied with eye masks at night in the duration of admission
eye masks
eye masks from 21:00 to 6:00 each night during admission
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
eye masks
eye masks from 21:00 to 6:00 each night during admission
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Consistent with the diagnosis of sepsis;
3. Written informed consent was obtained from patients or their family members.
Exclusion Criteria
2. With sleep disorders; mental illness; cancer; autoimmune diseases; dysfunction of liver or kidney;
3. History of using of immune-related drugs; melatonin receptor agonist or antagonist; sleep-aid or mental- related drugs;
4. History of accepting radiotherapy or chemotherapy;
5. Doing shift work before admission.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chen Yuanzhuo
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuanzhuo Chen, M.D.
Role: STUDY_CHAIR
Shanghai 10th People's Hospital
Wenjie Li, M.D.
Role: PRINCIPAL_INVESTIGATOR
Shanghai 10th People's Hospital
Huiqi Wang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Shanghai 10th People's Hospital
Chengjin Gao, M.D.
Role: STUDY_DIRECTOR
Shanghai 10th People's Hospital
Hu Peng, M.D.
Role: STUDY_DIRECTOR
Shanghai 10th People's Hospital
Yugang Zhuang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Shanghai 10th People's Hospital
Xiangyu Zhang, M.D.
Role: STUDY_DIRECTOR
Shanghai 10th People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Tenth Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
040114002
Identifier Type: -
Identifier Source: org_study_id